Clinical Trial

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-30 -> 2026-12-31 2026-08-12
notable Primary completion pushed: 2026-03-31 -> 2026-06-30 2026-04-21
Trial Details
NCT Number NCT02436707
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Janssen, LP, Roche Pharma AG, Karyopharm Therapeutics Inc
Conditions Lymphoma
Enrollment 129 participants
Start Date 2015-10-27
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-11